联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03933 联邦制药

未开盘 02-24 16:08:09

12.170

-0.410

-3.26%

最高12.600	最低12.090	成交量607.45万
今开12.600	昨收12.580	日振幅4.05%
总市值240.11亿	流通市值240.11亿	总股本19.73亿
成交额7,434万	换手率0.31%	流通股本19.73亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03933","market":"HK","secType":"STK","nameCN":"联邦制药","latestPrice":12.17,"timestamp":1771920489007,"preClose":12.58,"halted":0,"volume":6074463,"delay":0,"changeRate":-0.032591414944356134,"floatShares":1973000000,"shares":1973000000,"eps":1.463938,"marketStatus":"未开盘","change":-0.41,"latestTime":"02-24 16:08:09","open":12.6,"high":12.6,"low":12.09,"amount":74337061,"amplitude":0.040541,"askPrice":12.18,"askSize":128000,"bidPrice":12.17,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":1.702,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771983000000},"marketStatusCode":0,"adr":0,"listingDate":1181836800000,"exchange":"SEHK","adjPreClose":12.58,"dividendRate":0.04043,"openAndCloseTimeList":[[1771896600000,1771905600000],[1771909200000,1771920000000]],"volumeRatio":0.7183430764685197,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03933/wiki","defaultTab":"wiki","newsList":[{"id":"2613795944","title":"联邦制药(03933)：UBT251 注射液已完成在中国超重/肥胖患者中的 II 期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2613795944","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613795944?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:33","pubTimestamp":1771922037,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 公布，公司全资附属公司联邦生物科技有限公司自主研发的 1 类创新药 UBT251 注射液已完成在中国超重/肥胖患者中的 II 期临床研究。本研究结果显示，UBT251 各剂量组减重效果显著。UBT251 各剂量组整体安全性和耐受性良好，未发生因任何不良事件导致的退出。UBT251 注射液在超重/肥胖患者中的 II 期临床研究达到预期目标，支持其进入下一阶段临床研究。后续公司将尽快启动中国超重/肥胖患者的 III 期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f37ea4482eb71651542a4cd5fb933659","theme_name":"热榜No.33 · 诺和诺德与联合生物技术公司肥胖药物试验显著减重19.7%","theme_type":2,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联邦制药(03933)：UBT251 注射液已完成在中国超重/肥胖患者中的 II 期临床研究","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2614475077","title":"联邦制药02月24日遭主力抛售183.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614475077","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614475077?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:15","pubTimestamp":1771920955,"startTime":"0","endTime":"0","summary":"02月24日, 联邦制药股价跌3.26%，报收12.17元，成交金额7433.7万元，换手率0.31%，振幅4.05%，量比0.72。联邦制药今日主力资金净流出183.9万元，连续3日净流出，上一交易日主力净流出93.5万元。该股近5个交易日下跌3.49%，主力资金累计净流出979.0万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入2265.8万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224162119a7190d81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224162119a7190d81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2613780568","title":"每日卖空追踪 | 联邦制药 02月23日卖空量成交5.4万股，卖空比例为3.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613780568","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613780568?lang=zh_cn&edition=full","pubTime":"2026-02-23 16:30","pubTimestamp":1771835436,"startTime":"0","endTime":"0","summary":"联邦制药北京时间02月23日，涨1.86%，卖空量成交5.4万股，较上一交易日减少96.96%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163449a7156531&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163449a7156531&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2613214189","title":"每日卖空追踪 | 联邦制药 02月20日卖空量成交66.8万股，卖空比例为10.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613214189","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613214189?lang=zh_cn&edition=full","pubTime":"2026-02-20 16:30","pubTimestamp":1771576234,"startTime":"0","endTime":"0","summary":"联邦制药北京时间02月20日，跌1.91%，卖空量成交66.8万股，较上一交易日减少11.64%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220163500a4b5e95f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220163500a4b5e95f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2613214181","title":"联邦制药02月20日主力净流出233.2万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2613214181","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613214181?lang=zh_cn&edition=full","pubTime":"2026-02-20 16:15","pubTimestamp":1771575356,"startTime":"0","endTime":"0","summary":"02月20日, 联邦制药股价跌1.91%，报收12.35元，成交金额7737.8万元，换手率0.32%，振幅4.45%，量比0.58。联邦制药今日主力资金净流出233.2万元，上一交易日主力净流入305.1万元。该股近5个交易日下跌5.51%，主力资金累计净流出748.4万元；近20日主力资金累计净流入2488.9万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220161946a4b5de36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220161946a4b5de36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2612243987","title":"每日卖空追踪 | 联邦制药 02月16日卖空量成交75.6万股，卖空比例为42.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612243987","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612243987?lang=zh_cn&edition=full","pubTime":"2026-02-16 16:30","pubTimestamp":1771230632,"startTime":"0","endTime":"0","summary":"联邦制药北京时间02月16日，涨0.96%，卖空量成交75.6万股，较上一交易日减少84.03%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216163438a700dfed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216163438a700dfed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2610099361","title":"每日卖空追踪 | 联邦制药 02月11日卖空量成交58.6万股，卖空比例为8.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610099361","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610099361?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:30","pubTimestamp":1770798638,"startTime":"0","endTime":"0","summary":"联邦制药北京时间02月11日，涨0.15%，卖空量成交58.6万股，较上一交易日减少64.44%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163531a4973241&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163531a4973241&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2610693315","title":"诺和诺德：GLP-1/GIP/GCG启动减重二期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2610693315","media":"医药笔记","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610693315?lang=zh_cn&edition=full","pubTime":"2026-02-10 08:25","pubTimestamp":1770683156,"startTime":"0","endTime":"0","summary":"UBT251为联邦制药自主研发的GLP-1/GIP/GCG受体激动剂。2025年3月，联邦制药宣布将GLP-1/GIP/GCG受体激动剂UBT251的大中华区外全球权益授权给诺和诺德，后者支付2亿美元预付款、18亿美元里程碑金额，以及一定比例的销售分成。总结2025年12月，礼来公布GLP-1/GIP/GCG三靶点激动剂Retatrutide首个三期临数据，治疗肥胖合并骨关节炎三期临床TRIUMPH-4的最新数据，9mg、12mg Retatrutide治疗68周减重幅度分别为26.4%、28.7%，安慰剂组减重2.1%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021008564095407eb9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021008564095407eb9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","IE00BKVL7J92.USD","NVO","BK4532","BK4590","IE00BZ1G4Q59.USD","BK4585","NVOH","03933","BK4588","BK4599","LU1093756325.SGD","LU1093756168.USD","BK4144","NVOX","BK4007"],"gpt_icon":0},{"id":"2610972966","title":"新“自免药王”，联邦制药入局超25亿重磅明星药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2610972966","media":"北京药研汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610972966?lang=zh_cn&edition=full","pubTime":"2026-02-10 08:02","pubTimestamp":1770681722,"startTime":"0","endTime":"0","summary":"在非致命性皮肤疾病中，其疾病负担较重。据联邦制药新闻稿公示，拟定适应症为：特应性皮炎，本品用于治疗外用药控制不佳或不建议使用外用药的中重度特应性皮炎。2020年6月，度普利尤单抗首次在中国获批上市。2024年，度普利尤单抗全球销售额突破100亿美元，跻身全球畅销药TOP10；2024年以超140亿美元的销售额，成为了新一代的“自免药王”。目前，已通过谈判纳入国家乙类目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210091244a6e80d3d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210091244a6e80d3d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2610735650","title":"速递｜联邦制药三靶点减重药，UBT251切入OSA睡眠呼吸暂停","url":"https://stock-news.laohu8.com/highlight/detail?id=2610735650","media":"GLP1减重宝典","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610735650?lang=zh_cn&edition=full","pubTime":"2026-02-09 19:14","pubTimestamp":1770635694,"startTime":"0","endTime":"0","summary":"2月2日，联邦制药 全资附属公司联邦生物科技有限公司宣布，其自主研发的1类新药UBT251注射液，针对合并肥胖的中重度阻塞性睡眠呼吸暂停新适应症，已正式获得 国家药品监督管理局 批准开展临床试验。此前披露的1b期临床数据显示，在12周治疗周期内，UBT251最高剂量组患者平均减重幅度达到15.1%，同时安全性与耐受性表现良好。UBT251此次获批开展OSA相关临床研究，正是顺应了这一国际研发趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209225353a48fa9fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209225353a48fa9fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2610171636","title":"联邦制药(03933)：罗红霉素胶囊通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2610171636","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610171636?lang=zh_cn&edition=full","pubTime":"2026-02-09 18:09","pubTimestamp":1770631743,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 公布，公司全资附属公司珠海联邦制药股份有限公司中山分公司申报的罗红霉素胶囊通过中国国家药品监督管理局仿制药质量和疗效一致性评价。罗红霉素胶囊是第二代大环内酯类抗生素，具有耐酸性好、抗菌谱广、组织穿透性强、不良反应发生率较低等显著抗感染优势。临床适用于治疗由罗红霉素敏感病原体导致的耳鼻喉、呼吸道、皮肤及软组织、泌尿生殖道等感染。公司为首家通过罗红霉素胶囊剂型一致性评价的企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403224.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联邦制药(03933)：罗红霉素胶囊通过一致性评价","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2610650732","title":"每日卖空追踪 | 联邦制药 02月09日卖空量成交49.2万股，卖空比例为5.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610650732","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610650732?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:30","pubTimestamp":1770625836,"startTime":"0","endTime":"0","summary":"联邦制药北京时间02月09日，跌2.52%，卖空量成交49.2万股，较上一交易日减少92.23%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209164005a48e5e96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209164005a48e5e96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2609510392","title":"每日卖空追踪 | 联邦制药 02月06日卖空量成交454.2万股，卖空比例为18.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609510392","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609510392?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:30","pubTimestamp":1770366637,"startTime":"0","endTime":"0","summary":"联邦制药北京时间02月06日，涨3.56%，卖空量成交454.2万股，较上一交易日增加304.09%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206163617a483d0d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206163617a483d0d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2609551032","title":"联邦制药02月06日获主力加仓997.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609551032","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609551032?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:15","pubTimestamp":1770365715,"startTime":"0","endTime":"0","summary":"02月06日, 联邦制药股价涨3.56%，报收13.08元，成交金额3.3亿元，换手率1.27%，振幅9.34%，量比2.83。联邦制药今日主力资金净流入997.9万元，上一交易日主力净流入1970.9万元。该股近5个交易日上涨12.27%，主力资金累计净流入2997.6万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出2750.1万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206161554a6daac06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206161554a6daac06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2609534967","title":"联邦制药盘中涨超7% 瑞银认为市场低估UBT251销售潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2609534967","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609534967?lang=zh_cn&edition=full","pubTime":"2026-02-06 09:59","pubTimestamp":1770343140,"startTime":"0","endTime":"0","summary":"　　联邦制药盘中涨超7%，截至发稿，股价上涨5.62%，报13.34港元，成交额1.65亿港元。　　瑞银发布研报称，联邦制药是中国领先的药品制造商，拥有整合的业务线，涵盖中间产品与原料药，以及制剂产品。该行认为市场低估了UBT251的销售潜力，以及公司更广泛的创新研发管线。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-02-06/doc-inhkvvnm8215076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2609464433","title":"港股异动 | 联邦制药(03933)涨近3% 自研1类创新药UBT251注射液OSA适应症获临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2609464433","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609464433?lang=zh_cn&edition=full","pubTime":"2026-02-05 10:35","pubTimestamp":1770258928,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，联邦制药涨近3%，截至发稿，涨2.7%，报12.17港元，成交额5412.05万港元。消息面上，联邦制药发布公告，于2026年2月2日，本公司全资附属公司联邦生物科技有限公司自主研发的1类创新药UBT251注射液关于合并肥胖的中重度阻塞性睡眠呼吸暂停适应症获得中国国家药品监督管理局临床试验默示许可。作为中国首个化学合成GLP-1/GIP/GCG三靶点受体激动剂新药，UBT251助力本公司于该类药物研究领域占据重要地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK4585","VT","BK1191","03933","BK4588","BK1574","06978","VXUS","BK1161"],"gpt_icon":0},{"id":"2608822731","title":"联邦制药(03933)：UBT251 注射液OSA适应症获临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2608822731","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608822731?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:41","pubTimestamp":1770115313,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 发布公告，于2026年2月2日，本公司全资附属公司联邦生物科技有限公司自主研发的1类创新药UBT251注射液关于合并肥胖的中重度阻塞性睡眠呼吸暂停适应症获得中国国家药品监督管理局临床试验默示许可，受理号为CXHL2501306。以GLP-1类为代表的减重药物，有望填补OSA治疗领域大量未被满足的临床需求。此外，UBT251 注射液的超重或肥胖、2 型糖尿病、代谢相关脂肪性肝炎及慢性肾脏病适应症已于中国开展II期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联邦制药(03933)：UBT251 注射液OSA适应症获临床试验默示许可","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2608888327","title":"医药生物行业跟踪周报：降息等多因素支持科研上游持续复苏 重点推荐皓元医药、奥浦迈等","url":"https://stock-news.laohu8.com/highlight/detail?id=2608888327","media":"东吴证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608888327?lang=zh_cn&edition=full","pubTime":"2026-02-01 00:00","pubTimestamp":1769875200,"startTime":"0","endTime":"0","summary":"建议关注皓元医药、百奥赛图、百普赛斯、奥浦迈、药康生物、纳微科技和阿拉丁等。从小核酸角度，建议关注前沿生物、福元医药、悦康药业等。从GLP1 角度，建议关注联邦制药、博瑞医药、众生药业、信达生物等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260201204647a46f7473&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260201204647a46f7473&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1161","06978","09606","03933","BK1574"],"gpt_icon":0},{"id":"2607835560","title":"每日卖空追踪 | 联邦制药 01月29日卖空量成交17.4万股，卖空比例为2.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607835560","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607835560?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:30","pubTimestamp":1769675437,"startTime":"0","endTime":"0","summary":"联邦制药北京时间01月29日，跌0.25%，卖空量成交17.4万股，较上一交易日减少90.46%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129164156a6bae550&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129164156a6bae550&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2606718509","title":"联邦制药(03933)：注射用TUL108获美国FDA新药临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2606718509","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606718509?lang=zh_cn&edition=full","pubTime":"2026-01-28 19:18","pubTimestamp":1769599139,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 发布公告，于2026年1月28日，由公司全资附属公司珠海联邦制药股份有限公司自主研发的1类创新药注射用TUL108的新药临床试验注册申请获美国食品药品监督管理局批准，IND编号为178724。TUL108联合美罗培南对碳青霉烯类耐药大肠埃希菌、肺炎克雷伯菌、铜绿假单胞菌及鲍曼不动杆菌等均具有高度敏感性，针对临床极待解决的对碳青霉烯耐药的革兰阴性菌可实现全覆盖。注射用TUL108的研发将强化公司于抗感染领域的优势地位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398691.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联邦制药(03933)：注射用TUL108获美国FDA新药临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","03933"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tul.com.cn","stockEarnings":[{"period":"1week","weight":-0.0334},{"period":"1month","weight":0.034},{"period":"3month","weight":-0.0455},{"period":"6month","weight":-0.1754},{"period":"1year","weight":-0.0494},{"period":"ytd","weight":0.05}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.006},{"period":"3month","weight":0.0255},{"period":"6month","weight":0.0637},{"period":"1year","weight":0.1392},{"period":"ytd","weight":0.0374}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"联邦制药国际控股有限公司是一家投资控股公司，主要从事销售中间体产品、原料药及制剂产品业务。该公司通过三个业务部门运营业务。中间体部从事销售中间体产品业务。原料药部从事销售原料药业务。制剂产品部从事销售抗生素制剂产品、非抗生素制剂产品及空心胶囊业务。该公司通过其子公司还从事制造及销售有机化肥业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.368421,"avgChangeRate":-0.033088},{"month":2,"riseRate":0.736842,"avgChangeRate":0.072332},{"month":3,"riseRate":0.666667,"avgChangeRate":0.040428},{"month":4,"riseRate":0.611111,"avgChangeRate":0.081119},{"month":5,"riseRate":0.666667,"avgChangeRate":0.040685},{"month":6,"riseRate":0.277778,"avgChangeRate":-0.012388},{"month":7,"riseRate":0.526316,"avgChangeRate":0.011895},{"month":8,"riseRate":0.473684,"avgChangeRate":0.025474},{"month":9,"riseRate":0.421053,"avgChangeRate":-0.006971},{"month":10,"riseRate":0.631579,"avgChangeRate":-0.000903},{"month":11,"riseRate":0.473684,"avgChangeRate":-0.023163},{"month":12,"riseRate":0.421053,"avgChangeRate":0.011153}],"exchange":"SEHK","name":"联邦制药","nameEN":"UNITED LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供联邦制药(03933)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"联邦制药,03933,联邦制药股票,联邦制药股票老虎,联邦制药股票老虎国际,联邦制药行情,联邦制药股票行情,联邦制药股价,联邦制药股市,联邦制药股票价格,联邦制药股票交易,联邦制药股票购买,联邦制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供联邦制药(03933)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}